דילוג לתוכן הראשי
xMedica

NCT06605404ClinicalTrials.gov

Pan-tumor MRD Study

Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers

מגייסמקבל משתתפים כעת, לפי רשומת המרשם.
יצירת קשר עם המחקר

בקצרה

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to…

תצפיתידרושים 1,350 משתתפים47 אתריםמדינה אחת

קטגוריות

רשום במרשם אחד

מחקר יחיד יכול להיות רשום בכמה מרשמים. אנו מציגים אותו פעם אחת ומקשרים לכל רשומה שברשותנו.

מידע הניסוי מוצג כפי שפורסם על ידי המרשם, בשפת המקור שלו.

מתעניינים במחקר הזה?

התחברות או צרו חשבון כדי לרשום את התעניינותכם ולעקוב אחר המחקר הזה.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2024-09-20; recorded start 2025-01-08
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Not stated: No other studies from this sponsor are in this databaseCounted from the lead sponsor named in the record (Paradigm Health)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 7 conditions.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Masking not stated in the record

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 2 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study: 1,350 participants (target), run at 47 sites.

How this score is built
  • Enrolment31/40

    1,350 participants (target)

  • Site count4/25

    2 sites

  • Country count0/15

    Single country

  • Planned duration10/10

    Planned over about 88 months

  • Sponsor scale0/10

    Paradigm Health has led 1 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

תקציר

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back. Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.

מצבים רפואיים

  • Muscle Invasive Bladder Urothelial Carcinoma
  • Esophageal Cancer
  • Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
  • Melanoma (Skin Cancer)
  • NSCLC (Non-small Cell Lung Cancer)
  • Pancreatic (Exocrine Only)
  • Mix of Solid Tumors (MOST)

זכאות

זכאות
מיןהכול
גילאים18 Years – ללא מקסימום
מתנדבים בריאיםלא
שיטת דגימהNON_PROBABILITY_SAMPLE

אוכלוסיית המחקר

Study participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors

זכאות כפי שנכתבה במרשם

Eligibility Criteria: 1. Age 18 years or older. 2. Confirmed histological or cytological diagnosis of a malignant solid tumor that is either specified in one of the pre-defined tumor cohorts or meets the enrollment criteria for the Mix of Solid Tumors (MOST) cohort (Table 1). 3. Eligible for curative intent therapy, with surgical resection of cancer planned. a. If surgical resection has occurred, enrollment should occur within 3 months of surgical resection and before initiation of adjuvant therapy. 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2. 5. No systemic therapy for current cancer diagnosis administered before enrollment. 6. Willing and able to comply with required study procedures, including blood sample collection and primary tumor tissue submission from diagnostic biopsy or surgical excision. 7. Has completed all therapy (including endocrine therapy) 3 or more years ago for any previous invasive solid organ malignancy (with exception of nonmelanoma skin cancers) or hematologic malignancy. Individuals with a prior history of noninvasive (in situ) carcinomas may participate if they have received definitive treatment (no washout period required). 8. No concurrent diagnosis of another invasive cancer, except for nonmelanoma skin cancers. 9. No prior allogeneic hematopoietic stem cell transplant. 10. Able and willing to provide informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for the release of personal health information. Cohort Specific Criteria 11. Muscle-invasive urothelial carcinoma of the bladder and Melanoma Cohorts: Stage II or operable III cancer: 12. Esophageal, Gastric/GEJ, and NSCLC Cohorts: Stage I, II, or operable III cancer. 13. Pancreatic Cohort: Stage I, II or operable III cancer, exocrine only disease. 14. MOST cohort: Stage II or operable stage III solid tumor diagnosis that meets eligibility criteria and is not included in the other cohorts. The following tumor types are excluded: 1. Central nervous system (CNS) malignancies 2. Colorectal cancer 3. Breast cancer 4. Squamous cell skin cancer 5. Basal cell carcinoma 6. Gastrointestinal stromal tumors (GIST) 7. Thyroid cancer 8. Uveal melanoma 9. Low or intermediate grade neuroendocrine tumors ■ Eligible tumor types: High-grade neuroendocrine tumors, including neuroendocrine carcinomas, Merkel cell carcinomas, and small cell lung cancer are permissible 10. Hematologic cancers including multiple myeloma or other plasma cell dyscrasias, Hodgkin\'s lymphoma, non-Hodgkin\'s lymphoma, acute or chronic leukemias including chronic lymphocytic leukemia / small lymphocytic leukemia

זכאות במשפטים פשוטים

הקריטריונים של רשומה זו טרם פורקו למשפטים נפרדים. טקסט המרשם שלמעלה שלם והוא הגרסה המחייבת.

תכנון המחקר

תכנון המחקר
סוג המחקרתצפיתי
שלבלא צוין ברשומת המרשם
הקצאהלא צוין ברשומת המרשם
מודל ההתערבותלא צוין ברשומת המרשם
מטרה ראשיתלא צוין ברשומת המרשם
הסתרהלא צוין ברשומת המרשם
גיוסדרושים 1,350 משתתפים

נותן חסות ושותפים

  • Paradigm Health נותן חסות

זרועות והתערבויות

  • Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)

    Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)

  • Esophageal

    Esophageal cancer

  • Gastric and Gastroesophageal Junction (GEJ)

    Gastric and Gastroesophageal Junction (GEJ)

  • Melanoma

    Melanoma

  • Non-small cell lung (NSCLC)

    Non-small cell lung (NSCLC)

  • Pancreatic (exocrine only)

    Pancreatic (exocrine only)

  • Mix of Solid Tumors (MOST)

    Mix of Solid Tumors (MOST)

התערבויות

  • בדיקה אבחנתית blood and tissue samples

    routine standard of care

  • אחר blood and tissue samples

    Routine standard of care

מדדי תוצאה

  1. מדד תוצאה ראשוני

    Blood and tissue biospecimen registry

    To establish a blood and tissue biospecimen resource in participants with operable solid tumors, with clinical, lab, radiographic, and pathology annotation for the discovery, development, and validation of MRD assays.

    מסגרת זמן Observation from enrollment to 5.5 years after enrollment

תאריכים

תאריכים
תאריך התחלה8 בינואר 2025 (בפועל)
סיום ראשוני1 בדצמבר 2031 (משוער)
סיום1 באפריל 2032 (משוער)
פורסם לראשונה20 בספטמבר 2024 (בפועל)
עודכן לאחרונה24 בספטמבר 2026
התוצאות פורסמולא צוין ברשומת המרשם
המצב אומת לאחרונהספטמבר 2026

בפועל פירושו שהאירוע התרחש. משוער פירושו שנותן החסות צופה אותו. שתי המשמעויות שונות זו מזו.

מיקומים

47 אתרים מגייסים

United States

United States
מתקןעירמדינה או אזורמצב
Piedmont Cancer InstituteAtlantaGeorgiaמגייס
Guthrie Lourdes Memorial Hospital (GLMH)BinghamtonNew Yorkמגייס
Alabama OncologyBirminghamAlabamaמגייס
Mohtaseb Cancer Center and Blood DisordersBullhead CityArizonaמגייס
Gabrail Cancer CenterCantonOhioמגייס
Cancer & Blood Specialists of ArizonaCasa GrandeArizonaמגייס
Carolina Oncology SpecialistsCharlotteNorth Carolinaמגייס
Oncology & Hematology Associates of West BrowardCoral SpringsFloridaמגייס
Baptist Health CorbinCorbinKentuckyמגייס
Pontchartrain Cancer CenterCovingtonLouisianaמגייס
Baptist Health HardinElizabethtownKentuckyמגייס
The Melanoma and Skin Cancer InstituteEnglewoodColoradoמגייס
San Juan Oncology AssociatesFarmingtonNew Mexicoמגייס
Los Angeles Cancer Network (LACN)GlendaleCaliforniaמגייס
Southeastern Medical Oncology Center (SMOC)GoldsboroNorth Carolinaמגייס
The Cancer & Hematology Centers (CHC)Grand RapidsMichiganמגייס
Onocology Consultants P.A. (Oncology Consultants [OC Houston])HoustonTexasמגייס
Community Clinical TrialsKingwoodTexasמגייס
Lancaster General Hospital (UPenn)LancasterPennsylvaniaמגייס
Baptist Health LexingtonLexingtonKentuckyמגייס
Cancer Partners of NebraskaLincolnNebraskaמגייס
CARTILittle RockArkansasמגייס
Baptist Health LouisvilleLouisvilleKentuckyמגייס
Taylor Cancer Research CenterMaumeeOhioמגייס
Cancer Care Specialists of Illinois (CCSI)O'FallonIllinoisמגייס
Mid Florida Cancer CentersOrange CityFloridaמגייס
Ventura County Hematology Oncology SpecialistsOxnardCaliforniaמגייס
Oregon Health & Science University (OHSU)PortlandOregonמגייס
Virginia Cancer InstituteRichmondVirginiaמגייס
Mayo ClinicRochesterMinnesotaמגייס
Medical Oncology Associates of San Diego (MOASD)San DiegoCaliforniaמגייס
Medical Oncology Associates of San DiegoSan DiegoCaliforniaמגייס
Guthrie FoundationSayrePennsylvaniaמגייס
New York Cancer & Blood SpecialistsShirleyNew Yorkמגייס
Christus Health HighlandsShreveportLouisianaמגייס
Highlands Oncology Group (HOG)SpringdaleArkansasמגייס
Cox HealthSpringfieldMissouriמגייס
Comprehensive Hematology Oncology (CHO)St. PetersburgFloridaמגייס
Stockton Hematology Oncology Med GroupStocktonCaliforniaמגייס
Northwest Medical Specialties (NWMS)TacomaWashingtonמגייס
Christus St. Michael'sTexarkanaTexasמגייס
Cotton O'Neil Cancer Center [Stormont Vail]TopekaKansasמגייס
Oklahoma Cancer Specialists and Research Institute (OCSRI)TulsaOklahomaמגייס
Carle HealthUrbanaIllinoisמגייס
Cancer Center of KansasWichitaKansasמגייס
Regional Medical Oncology CenterWilsonNorth Carolinaמגייס
Cancer Care Associates of York (CCAY)YorkPennsylvaniaמגייס

מסמכי המחקר

לא צורפו מסמכים ברשומת מרשם זו.

שינויים לאורך זמן

  1. 24 בספטמבר 2026

    אתר נוסף

    45 sites added (47 total)

    247